Loading company…
NA Vaccine Institute develops vaccines, immune enhancers and therapies.
NA Vaccine Institute works on vaccine and therapeutic products including Nexavant®, PeptoVac® and PulmonoVac®. Its research also includes anti-cancer therapies using PD1 antibodies. Founded in 2018, the company is based in Seoul, South Korea. It raised KRW 17 billion in Series B funding in 2021, led by investors including DS Asset Management and DSC Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in